# XenoPort

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xenoport

- Industry: Biotechnology
- Headquarters: Santa Clara, US
- Website: www.xenoport.com
- Total disclosed funding: $152M
- Latest round: Series D (Dec 15, 2004)
- Investors on record: 19

## About

XenoPort Inc. is a biopharmaceutical company focused on developing novel therapeutics to improve the treatment of neurological diseases. It aims to enhance the quality of life for patients through innovative drug delivery systems.Founded in 1999 in Santa Clara, US, XenoPort Inc. specializes in developing new medications for neurological conditions. The company transitioned its strategy with a focus on innovative drug delivery technologies. It has completed a PIPE funding round in June 2005, raising USD 20.00 mn, which constitutes the total amount raised. The company has engaged in a total of 9 deals, with its last deal occurring on June 1, 2005. It was founded by individuals who have yet to be named; however, specific details about their prior ventures are currently unavailable.XenoPort Inc. develops and commercializes promising drugs aimed at treating neurological disorders. The company combines scientific research with advanced drug delivery systems to create therapeutics that meet unmet medical needs. Their products focus on improving patient outcomes and providing enhanced therapeutic benefits through innovative formulations.In the most recent year, 2015, XenoPort reported a revenue of USD 41.16 mn, with an EBITDA of USD -78.08 mn, indicating a negative earnings performance for that period.Looking forward, XenoPort Inc. plans to leverage its recent funding from the PIPE round to accelerate the development of its new drug candidates aimed at neurological conditions. The company aims to expand into new geographic markets, specifically targeting regions in North America and Europe by 2025. The capital raised will support product development and market entry strategies to enhance its therapeutic offerings.

## Funding rounds

- Series D, Dec 15, 2004, $25M — ARCH Venture Partners, Granite Asia, Skyline Ventures, Venrock, Frazier Technology Ventures, SunAmerica Ventures
- Series C, Feb 4, 2004, $37M — ARCH Venture Partners, Frazier Healthcare Partners, OrbiMed Advisors, HBM Partners, Novartis Venture Fund, Lilly Ventures, Granite Asia, Presidio Partners, Venrock, Invus [DUP], Lombard Odier Asset Management, Montgomery & Co., West River Group, SunAmerica Ventures, Lotus Biosciences Ventures
- Series C, Jun 10, 2002, $44M — ARCH Venture Partners, Frazier Healthcare Partners, OrbiMed Advisors, HBM Partners, Novartis Venture Fund, Lilly Ventures, Skyline Ventures, Presidio Partners, Venrock, Invus [DUP], Lombard Odier Asset Management, Lotus Biosciences Ventures
- Series B, Nov 1, 2000, $31M — OrbiMed Advisors, Skyline Ventures, Presidio Partners, Venrock, Lombard Odier Asset Management, Mass General Brigham Ventures, Frazier & Company
- Series A, Feb 1, 2000, $16M — ARCH Venture Partners, OrbiMed Advisors, Skyline Ventures, Presidio Partners, Venrock, Lombard Odier Asset Management, Frazier & Company

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C, Series D
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A, Series B, Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series C, Series D
- Lombard Odier Asset Management — Series A, Series B, Series C
- Frazier & Company — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series C
- Invus [DUP] — Series C
- Lotus Biosciences Ventures (https://capitalatlas.ai/funds/lotus-biosciences-ventures) — Series C
- Granite Asia (https://capitalatlas.ai/funds/granite-asia) — Series C, Series D
- Montgomery & Co. — Series C
- West River Group — Series C
- SunAmerica Ventures — Series C, Series D
- Frazier Technology Ventures (https://capitalatlas.ai/funds/frazier-technology-ventures) — Series D